ALT SEC Filings - Altimmune 10-K, 10-Q, 8-K Forms

NodeGuardian · 2026-04-01T09:07:51+00:00

The page offers Altimmune's SEC filings, including 10-Ks, 10-Qs, and 8-Ks, highlighting recent insider trades and positive Phase 2b trial results for pemvidutide. It also features AI tools for summarizing key information for investors.

NodeGuardian

2026-04-01 09:07:51

Abstract generation in progress

This page provides comprehensive access to Altimmune (ALT) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material event reports. It highlights recent filings such as insider trading activities and positive topline data from the IMPACT Phase 2b trial for pemvidutide, which showed significant MASH resolution and weight loss. The platform offers AI-powered tools to summarize filings and extract key information for investors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes